According to filings with the U.S. Securities and Exchange Commission, Route 92 Medical is raising up to $50,398,458.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Tony Chou played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Route 92 Medical
About Route 92 Medical, Inc. Route 92 Medical is on a mission to improve outcomes for patients undergoing minimally invasive brain procedures. At the core is a reconsidered procedural approach, cutting-edge engineering, and innovative product design. Our portfolio takes aim at the biggest challenges in neurointervention to deliver meaningful solutions to treat challenging diseases such as stroke. Founded by physicians, the company is focused upon developing thoughtful next generation products in collaboration with the worlds leading clinicians with the goal of improving procedural and patient outcomes. The Monopoint operating platform received U.S. FDA 510(k) clearance in 2020. The company is currently enrolling the SUMMIT MAX randomized controlled trial under an FDA-approved Investigational Device Exemption.

To learn more about Route 92 Medical, visit http://www.route92medical.com/
Route 92 Medical Linkedin Page: https://www.linkedin.com/company/route-92-medical/

Contact:
Tony Chou, Chief Executive Officer
650-581-1179
https://www.linkedin.com/in/tonychouverticalgroup/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.